Senti Biosciences

SNTI · United States

Share price · SNTI

$0.09-0.34 (-79.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 476K (0.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SNTI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-28.7%
  2. 2 Nov 2026+13.9%
  3. 30 Oct 2026-23.9%
  4. 28 Oct 2026+15.2%
  5. 22 Oct 2026-12.4%
  6. 13 Oct 2026-20.0%
  7. 14 Aug 2026+16.9%

    Nothing announced by SNTI that day or the session before.

  8. 16 Jul 2026-21.1%
  9. 15 Jul 2026-39.8%
  10. 24 Jun 2026+16.8%

Share of unusual movement by asset

For each asset, the share of SNTI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
SENTI-202
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—88%
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—10%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1
CD33 and/or FLT3 (activating antigens), EMCN (inhibitory NOT-gate)Cell therapy
Acute Myeloid Leukemia
Phase 1
GPC3 (CAR-NK, calibrated IL-15)Cell therapy
Hepatocellular Carcinoma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2<$0.1M$7.8M$7.9M$13M-$14M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1<$0.1M$5.3M$12M$4.2M-$7.5M operating cash flowreport ↗
2025-Q3—$11M$16M$18M-$9.4M operating cash flowreport ↗
2025-Q2—$10M$25M$15M-$13M operating cash flowreport ↗
2025-Q1$0$9.3M$37M$14M-$14M operating cash flowreport ↗
2024-Q3$0$8.7M$14M$29M-$7.9M operating cash flowreport ↗
2024-Q2$0$9.2M$19M$11M-$8.3M operating cash flowreport ↗
2024-Q1$0$8.8M$28M$12M-$12M operating cash flowreport ↗
2023-Q4——$39M+ $0 short-term inv.$71M-$7.0M operating cash flowreport ↗
2023-Q3$0.3M$9.1M$46M+ $0 short-term inv.$15M-$15M operating cash flowreport ↗
2023-Q2$0.7M$11M$40M+ $23M short-term inv.$19M-$14M operating cash flowreport ↗
2023-Q1$1.0M$11M$35M+ $45M short-term inv.$19M-$16M operating cash flowreport ↗
2022-Q4——$61M+ $41M short-term inv.$58M-$9.0M operating cash flowreport ↗
2022-Q3$1.5M$8.1M$118M$17M-$10M operating cash flowreport ↗
2022-Q2$1.1M$9.3M$143M$12M-$15M operating cash flowreport ↗
2022-Q1$0.8M$7.6M$0.4M$1.3M-$0.5M operating cash flowreport ↗
2021-Q3$0.9M$5.4M$75M$0.3M-$0.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY<$0.1M$38M$20M$15M-$43M operating cash flowreport ↗

Senti Biosciences reported FY2025 revenue of $0.02M versus $0M YoY, and R&D spend of $37.59M, up 9.4% YoY. Cash and equivalents were $19.95M, with a net loss of $61.44M and a quarterly net burn of $61.44M.

The company disclosed updated positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202 in relapsed/refractory acute myeloid leukemia, along with FDA Regenerative Medicine Advanced Therapy designation for SENTI-202. It also noted continued progress across its Gene Circuit engineered cell therapy pipeline and a focus on disciplined capital management to support key development milestones.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$34M$52M$13M-$41M operating cash flowreport ↗
2023-FY$2.0M$32M$39M+ $0 short-term inv.$18M-$52M operating cash flowreport ↗
2022-FY$3.3M$34M$61M+ $41M short-term inv.$15M-$35M operating cash flowreport ↗
2021-FY$2.3M$22M$0.9M+ $0 short-term inv.$14M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-21Lu Timothy K · director, CEOTax withholding157,312——Form 4
2026-10-21Rajangam Kanya · Pres. & Chief Med. & Dev. Off.Tax withholding19,953——Form 4
2026-03-09Lu Timothy K · director, CEOTax withholding80,666——Form 4
2026-03-09Rajangam Kanya · Pres. & Chief Med. & Dev. Off.Tax withholding10,757——Form 4
2026-02-02Lu Timothy K · director, CEOTax withholding4,191——Form 4
2026-02-02Rajangam Kanya · Pres. & Chief Med. & Dev. Off.Tax withholding1,384——Form 4
2025-07-18Baum Bryan Daniel · directorAward / grant (derivative)43,900——Form 4
2025-06-25Mathers Edward T · directorAward / grant (derivative)21,950——Form 4